Pfizer/$PFE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.

Ticker

$PFE
Sector

Primary listing

NYSE

Employees

81,000

Pfizer Metrics

BasicAdvanced
$156B
14.45
$1.89
0.46
$1.71
6.28%

What the Analysts think about Pfizer

Analyst ratings (Buy, Hold, Sell) for Pfizer stock.

Bulls say / Bears say

Pfizer raised its full-year profit outlook for 2025 after second-quarter revenue of $14.65 billion surpassed forecasts, driven by strong sales of Vyndaqel and Eliquis, highlighting solid momentum in its core business.
The nearly $7.3 billion takeover of Metsera gives Pfizer a leading spot in the fast-growing anti-obesity market thanks to Metsera’s GLP-1-based weight-loss products, expanding Pfizer’s drug pipeline.
Pfizer’s deal with the U.S. government includes a $70 billion pledge to domestic research, development, and manufacturing over three years, bolstering long-term innovation and supply chain stability.
Pfizer stopped developing its oral weight-loss drug candidate danuglipron due to safety issues, which delays its entry into the obesity market and lets rivals gain ground.
A September agreement requires Pfizer to match Medicaid drug prices to those in other developed countries, which could put pressure on U.S. pharmaceutical margins, even though there are tariff exemptions.
Even as Pfizer expands into the obesity market, it faces tough competition from Novo Nordisk and Eli Lilly, whose GLP-1 therapies already have strong brand presence, scale, and prescribing channels.
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

Pfizer Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Pfizer Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PFE

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs